We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · January 15, 2022

Beta Blockers and Renin–Angiotensin System Inhibitors for Preventing LV Dysfunction Due to Anthracyclines or Trastuzumab in Patients With Breast Cancer

European Heart Journal

 

Additional Info

European Heart Journal
A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer
Eur Heart J 2021 Dec 24;[EPub Ahead of Print], C Lewinter, TH Nielsen, LR Edfors, C Linde, JM Bland, M LeWinter, JGF Cleland, L Køber, F Braunschweig, A Mansson-Broberg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading